Article snippets. Full story url at the bottom.
VANCOUVER, British Columbia – Patients with multiple sclerosis (MS) taking ocrelizumab, an anti-CD20 B-cell-depleting humanized monoclonal antibody, are more likely to achieve no evidence of disease activity (NEDA) than those taking interferon beta-1a, researchers from the pivotal OPERA I and OPERA II phase 3 trials reported.
NEDA—a composite measure defined as no MS relapses, no confirmed disability progression, and no new or enlarging T2 lesions or gadolinium-enhancing T1 lesions—is increasingly becoming the treatment goal in MS.
“One truly exciting thing for patients with this type of treatment approach is the confidence of high efficacy as well as the convenience,” he said. “You only have to take this treatment twice a year, compared with taking a pill every day or using a needle 3 times a week. This is a dramatic improvement in how we apply therapeutics to patients.”
http://www.neurologyadvisor.com/aan-...rticle/491125/
VANCOUVER, British Columbia – Patients with multiple sclerosis (MS) taking ocrelizumab, an anti-CD20 B-cell-depleting humanized monoclonal antibody, are more likely to achieve no evidence of disease activity (NEDA) than those taking interferon beta-1a, researchers from the pivotal OPERA I and OPERA II phase 3 trials reported.
NEDA—a composite measure defined as no MS relapses, no confirmed disability progression, and no new or enlarging T2 lesions or gadolinium-enhancing T1 lesions—is increasingly becoming the treatment goal in MS.
“One truly exciting thing for patients with this type of treatment approach is the confidence of high efficacy as well as the convenience,” he said. “You only have to take this treatment twice a year, compared with taking a pill every day or using a needle 3 times a week. This is a dramatic improvement in how we apply therapeutics to patients.”
http://www.neurologyadvisor.com/aan-...rticle/491125/